Previous 10 | Next 10 |
home / stock / tkphf / tkphf news
Takeda Pharmaceutical ( OTCPK:TKPHF ) gets a positive CHMP opinion recommending approval of the subcutaneous form of vedolizumab biologic for maintenance therapy in adults with moderately to severely active ulcerative colitis or Crohn's disease. More news on: Takeda Pharmaceutical Compan...
Takeda Pharmaceutical ( OTCPK:TKPHF ) announces that it landed FDA approval for priority review for the company’s supplemental new drug application to expand the use of Alunbrig as a first-line treatment for patients with anaplastic lymphoma kinase-positive metastatic non-small c...
This article is part of a series that provides an ongoing analysis of the changes made to John Paulson's 13F stock portfolio on a quarterly basis. It is based on Paulson's regulatory 13F Form filed on 02/14/2020. Please visit our Tracking John Paulson's Paulson & Company Portfolio serie...
Takeda Pharmaceutical Company Limited (TKPHF) Q4 2019 Earnings Conference Call February 04, 2020 8:00 AM ET Company Participants Takashi Okubo - Investor Relations Costa Saroukos - Chief Financial Officer Andrew Plump - President of R&D Conference Call Participants Jame...
Takeda Pharmaceutical ( OTCPK:TKPHF ) 9M results (¥): Revenues: 2,519.5B (+82.6%). More news on: Takeda Pharmaceutical Company Limited, Healthcare stocks news, Earnings news and commentary, , Read more ...
The following slide deck was published by Takeda Pharmaceutical Company Limited in conjunction with their 2020 Q3 earnings Read more ...
Takeda Pharmaceutical ( OTCPK:TKPHF ): 9M Non-GAAP EPS of ¥360.00; GAAP EPS of ¥27.00. More news on: Takeda Pharmaceutical Company Limited, Earnings news and commentary, Healthcare stocks news, Read more ...
Quick Take Arcutis Biotherapeutics ( ARQT ) intends to raise $125 million from the sale of its common stock in an IPO, per an amended registration statement . The company is advancing a pipeline of treatment candidates for various skin conditions. For its lead candidate, ARQT plans to h...
LogicBio Therapeutics (NASDAQ: LOGC ) announces a research collaboration with Takeda Pharmaceutical ( OTCPK:TKPHF ) to further develop LB-301 for the treatment of Crigler-Najjar syndrome. More news on: LogicBio Therapeutics, Inc., Takeda Pharmaceutical Company Limited, Takeda Pharmaceuti...
Shares of Wave Life Sciences (NASDAQ: WVE) , a clinical-stage biopharmaceutical, are plunging after the company closed the doors on its lead program. Suvodirsen flopped in a clinical trial, causing the stock to lose 53.7% as of 12:56 p.m. EST on Monday. Wave Life Sciences is developing ...
News, Short Squeeze, Breakout and More Instantly...
Takeda Pharmaceutical Co Ltd Company Name:
TKPHF Stock Symbol:
OTCMKTS Market:
Takeda Pharmaceutical Co Ltd Website:
Usinas Siderurgicas De Minas Gerais S.A. ADR (Representing Pref Share Cl A) (USNZY) is expected to report $0 for Q2 2024 CREATD INC. (CRTD) is expected to report for Q1 2024 Bluegreen Vacations Holding Corporation - Class B (BVHBB) is expected to report for Q1 2024 Senstar Technologie...
Verbund AG ADR (OEZVY) is expected to report for Q1 2024 Rent the Runway Inc. (RENT) is expected to report $-6.56 for Q1 2025 Johnson Matthey plc ADR (JMPLY) is expected to report for Q4 2024 RVL Pharmaceuticals plc (RVLPQ) is expected to report for Q1 2024 Ciena Corporation (CIEN...
JD.com Inc. (JD) is expected to report $0.56 for Q1 2024 Volkswagen AG (VLKAF) is expected to report for Q1 2024 CalAmp Corp. (CAMP) is expected to report for Q4 2024 Sonic Foundry Inc. (SOFO) is expected to report for Q2 2024 Moatable Inc ADR (R2RS:MU) is expected to report for Q...